tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Cosio FG and Larson TS Cardiovascular disease after transplantation: do we know all of the variables? 2003 Am. J. Transplant. pmid:12859523
Krämer BK et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. 2003 Am. J. Transplant. pmid:12859533
Ciancio G et al. The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients. 2003 Am. J. Transplant. pmid:12859538
Ellis CL and Racusen LC Mild rise in creatinine six months post kidney transplant. 2012 Am. J. Transplant. pmid:22845913
Xu H et al. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 2014 Am. J. Transplant. pmid:24472192
Qazi Y et al. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. 2017 Am. J. Transplant. pmid:27775865
Abdelmalek MF et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. 2012 Am. J. Transplant. pmid:22233522
Boudjema K et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. 2011 Am. J. Transplant. pmid:21466650
Coghill AE et al. Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort. 2016 Am. J. Transplant. pmid:26824445
Knechtle SJ Guidance for liver transplant immunosuppression. 2011 Am. J. Transplant. pmid:21466652
Asrani SK et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. 2014 Am. J. Transplant. pmid:24456026
Song L et al. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys. 2017 Am. J. Transplant. pmid:27598231
Egli A et al. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. 2010 Am. J. Transplant. pmid:20840474
Touzot M et al. Renal transplantation in HIV-infected patients: the Paris experience. 2010 Am. J. Transplant. pmid:20840478
Saikali JA et al. Sirolimus may promote thrombotic microangiopathy. 2003 Am. J. Transplant. pmid:12603218
Budde K et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 2014 Am. J. Transplant. pmid:25278376
Duncan FJ et al. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. 2007 Am. J. Transplant. pmid:17941958
Silva HT et al. Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. 2013 Am. J. Transplant. pmid:24266969
Ricciardelli I et al. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. 2013 Am. J. Transplant. pmid:24266973
Hu X et al. Chimeric Allografts Induced by Short-Term Treatment With Stem Cell-Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats. 2016 Am. J. Transplant. pmid:26749344
Suszynski TM et al. Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. 2013 Am. J. Transplant. pmid:23432755
Cameron AM et al. Chimeric Allografts Induced by Short-Term Treatment With Stem Cell Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: II, Study in Miniature Swine. 2016 Am. J. Transplant. pmid:26748958
Ferguson R et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. 2011 Am. J. Transplant. pmid:21114656
McKenna G and Trotter JF Does early (CNI) conversion lead to eternal (renal) salvation? 2010 Am. J. Transplant. pmid:20928938
Hanto DW et al. Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. 2010 Am. J. Transplant. pmid:20977633
Frassetto LA and Benet LZ Pharmacogenomics and transplantation: where are we? 2004 Am. J. Transplant. pmid:15147415
Hirsch HH et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. 2013 Am. J. Transplant. pmid:23137180
Naesens M et al. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. 2007 Am. J. Transplant. pmid:17608835
Koefoed-Nielsen PB et al. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. 2002 Am. J. Transplant. pmid:12099520
Klintmalm GB Immunosuppression, generic drugs and the FDA. 2011 Am. J. Transplant. pmid:21794082
Shihab FS et al. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. 2013 Am. J. Transplant. pmid:23167508
Forns X and Navasa M Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate. 2011 Am. J. Transplant. pmid:21797970
Wlodarczyk Z et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. 2009 Am. J. Transplant. pmid:19681813
Chisholm-Burns MA et al. Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. 2009 Am. J. Transplant. pmid:19681814
Schold JD and Kaplan B AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. 2009 Am. J. Transplant. pmid:19681827
Arnold R et al. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. 2013 Am. J. Transplant. pmid:23841745
Willicombe M et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. 2011 Am. J. Transplant. pmid:21299828
Muthusamy AS et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. 2008 Am. J. Transplant. pmid:18828772
Pirenne J et al. Tolerance of liver transplant patients to strenuous physical activity in high-altitude. 2004 Am. J. Transplant. pmid:15023147
Heisel O et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. 2004 Am. J. Transplant. pmid:15023151
Hardinger KL et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. 2004 Am. J. Transplant. pmid:15023155
Suwelack B et al. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. 2004 Am. J. Transplant. pmid:15023160
Srinivas TR et al. The noninferiority trial: don't don't do it. 2010 Am. J. Transplant. pmid:21087412
Vanrenterghem Y et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. 2005 Am. J. Transplant. pmid:15636615
Sindhi R et al. Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. 2005 Am. J. Transplant. pmid:15636616
Bryan CF et al. Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. 2007 Am. J. Transplant. pmid:17359511
Vincenti F et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. 2007 Am. J. Transplant. pmid:17359512
Busque S et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. 2009 Am. J. Transplant. pmid:19660021
Diaz-Siso JR et al. Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation. 2015 Am. J. Transplant. pmid:25777324
Cendales L et al. Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report. 2015 Am. J. Transplant. pmid:25773260
Klintmalm GB et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. 2014 Am. J. Transplant. pmid:25041339
Jaksch P et al. Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. 2014 Am. J. Transplant. pmid:25039364
TruneÄŒka P et al. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study. 2015 Am. J. Transplant. pmid:25707487
Adam R et al. Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. 2015 Am. J. Transplant. pmid:25703527
Asrani SK and O'Leary JG Can one pill a day keep rejection away? 2015 Am. J. Transplant. pmid:25703394
Bhorade SM et al. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. 2003 Am. J. Transplant. pmid:14629288
Madeleine MM et al. HPV-related cancers after solid organ transplantation in the United States. 2013 Am. J. Transplant. pmid:24119294
Oetting WS et al. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles. 2016 Am. J. Transplant. pmid:26485092
Pondrom S The AJT report. 2008 Am. J. Transplant. pmid:18324976
De Simone P et al. Everolimus with reduced tacrolimus in liver transplantation. 2013 Am. J. Transplant. pmid:23601137
Badri P et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. 2015 Am. J. Transplant. pmid:25708713
Chodoff L and Hamberg KJ Response to 'Different preparations of tacrolimus and medication errors'. 2009 Am. J. Transplant. pmid:19392982
Cherukuri A et al. An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. 2012 Am. J. Transplant. pmid:22390816
Larson TS et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. 2006 Am. J. Transplant. pmid:16468960
Vitko S et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. 2006 Am. J. Transplant. pmid:16468962
Barth RN et al. Vascularized bone marrow-based immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates. 2011 Am. J. Transplant. pmid:21668624
Chen G et al. A synergistic effect between PG490-88 and tacrolimus prolongs renal allograft survival in monkeys. 2006 Am. J. Transplant. pmid:16539628
Guirado L et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. 2011 Am. J. Transplant. pmid:21668633
Flechner SM et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. 2011 Am. J. Transplant. pmid:21668635
Budde K How to use mTOR inhibitors? The search goes on. 2011 Am. J. Transplant. pmid:21668636
Carenco C et al. Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship. 2015 Am. J. Transplant. pmid:25648361
Maes BD et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. 2002 Am. J. Transplant. pmid:12484345
Heller T et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. 2007 Am. J. Transplant. pmid:17532750
Schrepfer S et al. Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. 2007 Am. J. Transplant. pmid:17532751
Grenda R et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. 2010 Am. J. Transplant. pmid:20420639
Asberg A et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. 2010 Am. J. Transplant. pmid:20486914
Ryan CM and Swanson DP clinical research, innovative practice and IRB review: identifying and respecting boundaries. 2007 Am. J. Transplant. pmid:17331113
Hautz T et al. Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. 2010 Am. J. Transplant. pmid:20353468
Silva HT et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. 2007 Am. J. Transplant. pmid:17217442
Grinyo JM et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. 2004 Am. J. Transplant. pmid:15268733
Schussler T et al. Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. 2004 Am. J. Transplant. pmid:15268744
Bunnapradist S et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. 2013 Am. J. Transplant. pmid:23279614
Ceschi A et al. Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. 2013 Am. J. Transplant. pmid:23279718
Toso C et al. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. 2006 Am. J. Transplant. pmid:16611343
Lacaille F et al. Severe dysimmune cytopenia in children treated with tacrolimus after organ transplantation. 2006 Am. J. Transplant. pmid:16611346
Chamie K et al. The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer. 2008 Am. J. Transplant. pmid:18853950
Lefaucheur C et al. Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. 2008 Am. J. Transplant. pmid:18671673
Pech T et al. Intestinal regeneration, residual function and immunological priming following rescue therapy after rat small bowel transplantation. 2012 Am. J. Transplant. pmid:22974463
Kaplan B and Kirk AD Tacrolimus and sirolimus: when bad things happen to good drugs. 2006 Am. J. Transplant. pmid:16827845
McAlister VC et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. 2006 Am. J. Transplant. pmid:16827858
Gallon L et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. 2006 Am. J. Transplant. pmid:16827862
Grenda R et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. 2006 Am. J. Transplant. pmid:16827869
Haufroid V et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. 2006 Am. J. Transplant. pmid:17049058
Lake JR et al. Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. 2005 Am. J. Transplant. pmid:16303011
Pallet N et al. Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. 2016 Am. J. Transplant. pmid:26990694
Barbas AS et al. Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. 2013 Am. J. Transplant. pmid:23331705
Fujishiro J et al. Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation. 2010 Am. J. Transplant. pmid:20642681
Martinez F et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. 2010 Am. J. Transplant. pmid:20642691
Mandelbrot DA et al. Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus. 2015 Am. J. Transplant. pmid:26176342
Chhabra D et al. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. 2013 Am. J. Transplant. pmid:24007570